Update
$Matinas BioPharma (MTNB.US)$ Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-docetaxel
Management to host to 2023 Financial Results and Business Update Conference Call on March 27, 2024
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-docetaxel
Management to host to 2023 Financial Results and Business Update Conference Call on March 27, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment